213 related articles for article (PubMed ID: 32888499)
1. Assessing IRAK4 Functions in ABC DLBCL by IRAK4 Kinase Inhibition and Protein Degradation.
Zhang J; Fu L; Shen B; Liu Y; Wang W; Cai X; Kong L; Yan Y; Meng R; Zhang Z; Chen YP; Liu Q; Wan ZK; Zhou T; Wang X; Gavine P; Del Rosario A; Ahn K; Philippar U; Attar R; Yang J; Xu Y; Edwards JP; Dai X
Cell Chem Biol; 2020 Dec; 27(12):1500-1509.e13. PubMed ID: 32888499
[TBL] [Abstract][Full Text] [Related]
2. Selective interleukin-1 receptor-associated kinase 4 inhibitors for the treatment of autoimmune disorders and lymphoid malignancy.
Kelly PN; Romero DL; Yang Y; Shaffer AL; Chaudhary D; Robinson S; Miao W; Rui L; Westlin WF; Kapeller R; Staudt LM
J Exp Med; 2015 Dec; 212(13):2189-201. PubMed ID: 26621451
[TBL] [Abstract][Full Text] [Related]
3. Design and synthesis of Imidazo[1,2-b]pyridazine IRAK4 inhibitors for the treatment of mutant MYD88 L265P diffuse large B-cell lymphoma.
Chen Y; Bai G; Ning Y; Cai S; Zhang T; Song P; Zhou J; Duan W; Ding J; Xie H; Zhang H
Eur J Med Chem; 2020 Mar; 190():112092. PubMed ID: 32014679
[TBL] [Abstract][Full Text] [Related]
4. Discovery of Highly Potent and Selective IRAK1 Degraders to Probe Scaffolding Functions of IRAK1 in ABC DLBCL.
Fu L; Zhang J; Shen B; Kong L; Liu Y; Tu W; Wang W; Cai X; Wang X; Cheng N; Xia M; Zhou T; Liu Q; Xu Y; Yang J; Gavine P; Philippar U; Attar R; Edwards JP; Venable JD; Dai X
J Med Chem; 2021 Aug; 64(15):10878-10889. PubMed ID: 34279092
[TBL] [Abstract][Full Text] [Related]
5. Oncogenically active MYD88 mutations in human lymphoma.
Ngo VN; Young RM; Schmitz R; Jhavar S; Xiao W; Lim KH; Kohlhammer H; Xu W; Yang Y; Zhao H; Shaffer AL; Romesser P; Wright G; Powell J; Rosenwald A; Muller-Hermelink HK; Ott G; Gascoyne RD; Connors JM; Rimsza LM; Campo E; Jaffe ES; Delabie J; Smeland EB; Fisher RI; Braziel RM; Tubbs RR; Cook JR; Weisenburger DD; Chan WC; Staudt LM
Nature; 2011 Feb; 470(7332):115-9. PubMed ID: 21179087
[TBL] [Abstract][Full Text] [Related]
6. Discovery and Optimization of Pyrrolopyrimidine Inhibitors of Interleukin-1 Receptor Associated Kinase 4 (IRAK4) for the Treatment of Mutant MYD88
Scott JS; Degorce SL; Anjum R; Culshaw J; Davies RDM; Davies NL; Dillman KS; Dowling JE; Drew L; Ferguson AD; Groombridge SD; Halsall CT; Hudson JA; Lamont S; Lindsay NA; Marden SK; Mayo MF; Pease JE; Perkins DR; Pink JH; Robb GR; Rosen A; Shen M; McWhirter C; Wu D
J Med Chem; 2017 Dec; 60(24):10071-10091. PubMed ID: 29172502
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis and pharmacological evaluation of 2,3-dihydrobenzofuran IRAK4 inhibitors for the treatment of diffuse large B-cell lymphoma.
Chen Y; Ning Y; Chen Z; Xue Y; Wu Q; Duan W; Ding J; Zhou J; Xie H; Zhang H
Eur J Med Chem; 2023 Aug; 256():115453. PubMed ID: 37163947
[TBL] [Abstract][Full Text] [Related]
8. Optimization of permeability in a series of pyrrolotriazine inhibitors of IRAK4.
Degorce SL; Anjum R; Dillman KS; Drew L; Groombridge SD; Halsall CT; Lenz EM; Lindsay NA; Mayo MF; Pink JH; Robb GR; Scott JS; Stokes S; Xue Y
Bioorg Med Chem; 2018 Feb; 26(4):913-924. PubMed ID: 29398441
[TBL] [Abstract][Full Text] [Related]
9. Discovery of LC-MI-3: A Potent and Orally Bioavailable Degrader of Interleukin-1 Receptor-Associated Kinase 4 for the Treatment of Inflammatory Diseases.
Chen L; Luo R; Ma L; Xu Y; Cao J; Jiang Z; Chen S; Huang X; Zhang M; Zheng L; Zhang Y; Yin L; Yu J; Zheng X; Zheng L; Huang P; Liang G
J Med Chem; 2024 May; 67(10):8060-8076. PubMed ID: 38722184
[TBL] [Abstract][Full Text] [Related]
10. Discovery of a Series of 5-Azaquinazolines as Orally Efficacious IRAK4 Inhibitors Targeting MyD88
Degorce SL; Anjum R; Bloecher A; Carbajo RJ; Dillman KS; Drew L; Halsall CT; Lenz EM; Lindsay NA; Mayo MF; Pink JH; Robb GR; Rosen A; Scott JS; Xue Y
J Med Chem; 2019 Nov; 62(21):9918-9930. PubMed ID: 31622099
[TBL] [Abstract][Full Text] [Related]
11. IRAK4 kinase activity controls Toll-like receptor-induced inflammation through the transcription factor IRF5 in primary human monocytes.
Cushing L; Winkler A; Jelinsky SA; Lee K; Korver W; Hawtin R; Rao VR; Fleming M; Lin LL
J Biol Chem; 2017 Nov; 292(45):18689-18698. PubMed ID: 28924041
[TBL] [Abstract][Full Text] [Related]
12. Crystal structure of human IRAK1.
Wang L; Qiao Q; Ferrao R; Shen C; Hatcher JM; Buhrlage SJ; Gray NS; Wu H
Proc Natl Acad Sci U S A; 2017 Dec; 114(51):13507-13512. PubMed ID: 29208712
[TBL] [Abstract][Full Text] [Related]
13. Mechanism of dysfunction of human variants of the IRAK4 kinase and a role for its kinase activity in interleukin-1 receptor signaling.
De S; Karim F; Kiessu E; Cushing L; Lin LL; Ghandil P; Hoarau C; Casanova JL; Puel A; Rao VR
J Biol Chem; 2018 Sep; 293(39):15208-15220. PubMed ID: 30115681
[TBL] [Abstract][Full Text] [Related]
14. Interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitors: an updated patent review (2016-2018).
McElroy WT
Expert Opin Ther Pat; 2019 Apr; 29(4):243-259. PubMed ID: 30916602
[TBL] [Abstract][Full Text] [Related]
15. Identification of quinazoline based inhibitors of IRAK4 for the treatment of inflammation.
Smith GF; Altman MD; Andresen B; Baker J; Brubaker JD; Chen H; Chen Y; Childers M; Donofrio A; Ferguson H; Fischer C; Fischmann TO; Gibeau C; Hicks A; Jin S; Kattar S; Kleinschek MA; Leccese E; Lesburg C; Li C; Lim J; Liu D; Maclean JKF; Mansoor F; Moy LY; Mulrooney EF; Necheva AS; Presland J; Rakhilina L; Yang R; Torres L; Zhang-Hoover J; Northrup A
Bioorg Med Chem Lett; 2017 Jun; 27(12):2721-2726. PubMed ID: 28501511
[TBL] [Abstract][Full Text] [Related]
16. Improving metabolic stability and removing aldehyde oxidase liability in a 5-azaquinazoline series of IRAK4 inhibitors.
Degorce SL; Aagaard A; Anjum R; Cumming IA; Diène CR; Fallan C; Johnson T; Leuchowius KJ; Orton AL; Pearson S; Robb GR; Rosen A; Scarfe GB; Scott JS; Smith JM; Steward OR; Terstiege I; Tucker MJ; Turner P; Wilkinson SD; Wrigley GL; Xue Y
Bioorg Med Chem; 2020 Dec; 28(23):115815. PubMed ID: 33091850
[TBL] [Abstract][Full Text] [Related]
17. IRAK4 mediates colitis-induced tumorigenesis and chemoresistance in colorectal cancer.
Li Q; Chen Y; Zhang D; Grossman J; Li L; Khurana N; Jiang H; Grierson PM; Herndon J; DeNardo DG; Challen GA; Liu J; Ruzinova MB; Fields RC; Lim KH
JCI Insight; 2019 Oct; 4(19):. PubMed ID: 31527315
[TBL] [Abstract][Full Text] [Related]
18. Inhibitors of interleukin-1 receptor-associated kinase 4 (IRAK4): a patent review (2012-2015).
Seganish WM
Expert Opin Ther Pat; 2016 Aug; 26(8):917-32. PubMed ID: 27310003
[TBL] [Abstract][Full Text] [Related]
19. Discovery of Proteolysis-Targeting Chimera Molecules that Selectively Degrade the IRAK3 Pseudokinase.
Degorce SL; Tavana O; Banks E; Crafter C; Gingipalli L; Kouvchinov D; Mao Y; Pachl F; Solanki A; Valge-Archer V; Yang B; Edmondson SD
J Med Chem; 2020 Sep; 63(18):10460-10473. PubMed ID: 32803978
[TBL] [Abstract][Full Text] [Related]
20. IRAK4 inhibition to shut down TLR signaling in autoimmunity and MyD88-dependent lymphomas.
Küppers R
J Exp Med; 2015 Dec; 212(13):2184. PubMed ID: 26666751
[No Abstract] [Full Text] [Related]
[Next] [New Search]
